DocGo Inc.

NasdaqCM:DCGO Stock Report

Market Cap: US$123.2m

DocGo Valuation

Is DCGO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of DCGO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

US$150
Fair Value
99.2% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: DCGO ($1.2) is trading below our estimate of fair value ($149.88)

Significantly Below Fair Value: DCGO is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for DCGO?

Key metric: As DCGO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for DCGO. This is calculated by dividing DCGO's market cap by their current revenue.
What is DCGO's PS Ratio?
PS Ratio0.3x
SalesUS$435.97m
Market CapUS$123.24m

Price to Sales Ratio vs Peers

How does DCGO's PS Ratio compare to its peers?

The above table shows the PS ratio for DCGO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
INFU InfuSystem Holdings
1.4x8.02%US$200.6m
PIII P3 Health Partners
0.02x5.02%US$64.3m
MEHC.Q Chrome Holding
0.6xn/aUS$101.4m
NNOX Nano-X Imaging
22.1x50.48%US$276.9m
DCGO DocGo
0.3x-11.61%US$123.2m

Price-To-Sales vs Peers: DCGO is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (6x).

Price to Sales Ratio vs Industry

How does DCGO's PS Ratio compare vs other companies in the US Healthcare Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x7.69%US$94.00b
COR Cencora
0.2x6.44%US$60.22b
CAH Cardinal Health
0.2x7.82%US$37.48b
CNC Centene
0.1x4.32%US$18.88b
DCGO 0.3xIndustry Avg. 1.4xNo. of Companies27PS012345+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: DCGO is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Healthcare industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is DCGO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

DCGO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.2x

Price-To-Sales vs Fair Ratio: DCGO is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst DCGO forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.20
US$3.08
+156.30%
26.38%US$4.00US$1.60n/a6
Oct ’26US$1.31
US$3.08
+134.78%
26.38%US$4.00US$1.60n/a6
Sep ’26US$1.56
US$3.08
+97.16%
26.38%US$4.00US$1.60n/a6
Aug ’26US$1.33
US$3.05
+129.36%
28.11%US$4.00US$1.45n/a6
Jul ’26US$1.52
US$3.05
+100.69%
28.11%US$4.00US$1.45n/a6
Jun ’26US$1.42
US$3.05
+114.79%
28.11%US$4.00US$1.45n/a6
May ’26US$2.20
US$5.05
+129.52%
30.73%US$8.00US$2.85n/a7
Apr ’26US$2.68
US$5.05
+88.44%
30.73%US$8.00US$2.85n/a7
Mar ’26US$3.09
US$5.05
+63.44%
30.73%US$8.00US$2.85n/a7
Feb ’26US$4.89
US$6.21
+27.09%
18.17%US$8.00US$5.00n/a7
Jan ’26US$4.24
US$6.21
+46.57%
18.17%US$8.00US$5.00n/a7
Dec ’25US$4.33
US$6.21
+43.52%
18.17%US$8.00US$5.00n/a7
Nov ’25US$3.63
US$6.21
+71.19%
18.17%US$8.00US$5.00n/a7
Oct ’25US$3.35
US$6.21
+85.51%
18.17%US$8.00US$5.00US$1.317
Sep ’25US$3.78
US$6.21
+64.41%
18.17%US$8.00US$5.00US$1.567
Aug ’25US$3.48
US$7.07
+103.18%
26.84%US$11.00US$5.00US$1.337
Jul ’25US$2.93
US$7.07
+141.34%
26.84%US$11.00US$5.00US$1.527
Jun ’25US$2.93
US$7.07
+141.34%
26.84%US$11.00US$5.00US$1.427
May ’25US$3.39
US$9.67
+185.27%
18.22%US$12.00US$6.50US$2.207
Apr ’25US$4.04
US$10.74
+165.90%
13.34%US$13.00US$8.20US$2.687
Mar ’25US$4.13
US$10.74
+160.10%
13.34%US$13.00US$8.20US$3.097
Feb ’25US$3.60
US$12.14
+237.31%
10.25%US$14.00US$10.00US$4.897
Jan ’25US$5.59
US$12.72
+127.47%
14.39%US$16.00US$10.00US$4.247
Dec ’24US$6.01
US$12.72
+111.58%
14.39%US$16.00US$10.00US$4.337
Nov ’24US$6.09
US$13.29
+118.17%
9.62%US$16.00US$12.00US$3.637
Oct ’24US$5.33
US$13.29
+149.28%
9.62%US$16.00US$12.00US$3.357
US$3.08
Fair Value
59.0% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/09 21:25
End of Day Share Price 2025/10/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

DocGo Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarah JamesBarclays
Jenny ShenBTIG
David LarsenBTIG